Lupin logo

LUPIN - Lupin News Story

₹1178.45 -33.8  -2.8%

Last Trade - 11:26am

Sector
Healthcare
Size
Large Cap
Market Cap £5.32bn
Enterprise Value £5.53bn
Revenue £1.47bn
Position in Universe 81st / 3109

India's Strides Pharma halts U.S. sales of heartburn drug

Fri 27th September, 2019 7:24am
Sept 27 (Reuters) - India's Strides Pharma Science Ltd
 SRID.NS  said on Friday it has halted sales of its heartburn
drug Ranitidine in the U.S. market as it conducts tests to
identify possible cancer-causing impurities in the tablets.
    The move comes after the U.S. Food and Drug Administration
(FDA) asked the company to test the drug for indications of
N-nitrosodimethylamine (NDMA) impurity, which the regulator says
https://www.fda.gov/media/117807/download is a "probable human
carcinogen".
    Earlier this week, Dr. Reddy's Laboratories Ltd  REDY.NS 
and GlaxoSmithKline Pharmaceuticals Ltd  GLAX.NS  halted
Ranitidine distribution, while global companies such as Novartis
AG  NOVN.S  have stopped the supply of their versions of the
drug.  urn:newsml:reuters.com:*:nL3N2693A5
    The FDA flagged the presence of NDMA in Ranitidine samples
two weeks ago, while European regulators were assessing its
presence in the drug.  urn:newsml:reuters.com:*:nL3N2642CJ
    Meanwhile, the Canadian drug regulator said the lots of 
medicines being recalled may have been made using an active
ingredient containing NDMA above accepted levels, as it urged
companies to stop distributing Ranitidine.  urn:newsml:reuters.com:*:nL3N26G45R
 urn:newsml:reuters.com:*:nFWN2680I8

 (Reporting by Nallur Sethuraman in Bengaluru; Editing by
Subhranshu Sahu)
 ((Sethuraman.NR@thomsonreuters.com; (+91 8067496031); Reuters
Messaging: nallur.sethuraman.thomsonreuters.com@reuters.net))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.